Allergan (AGN) Tops Q4 EPS by 12c, Reports Mixed FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Allergen (AGN) PT Raised to $215 at Credit Suisse; 'Positive CGRP Data Should Relieve Pain AGN Investors Have Been Feeling'
February 7, 2018 8:12 AM ESTCredit Suisse raised its price target on Allergen (NYSE: AGN) to $215.00 (from $214.00) while maintaining a Outperform rating.
... MoreAllergen (AGN) PT Raised to $242 at Leerink Partners
February 7, 2018 7:39 AM ESTLeerink Partners raised its price target on Allergen (NYSE: AGN) to $242.00 (from $237.00) while maintaining a Outperform rating.
Analyst Seamus Fernandez commented, "Following Tuesdays call we are incrementally more confident in the approvability of ubrogepant for acute migraine and AGNs ability to execute on 2018... More
